Detail of the clinical trial

Title of the trial A Randomized Two-Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phase or in Myeloid or Lymphoid Blast Phase or with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
EudraCT number 2005-001169-32
Protocol number CA180-035
Sponsor Bristol-Myers Squibb International Corporation, Brussels, Belgium
Indications Hemato-oncology
Diagnosis myeloid leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2005
Date of approval by Institute (SÚKL) 09.09.2005
Date of approval by EC 29.09.2005
Date of initiation CT in ČR 22.11.2005
Date of ending CT in ČR 5.8.2011
Notice
Sites Interní hematoonkologická klinika, Fakultní nemocnice Brno-Bohunice, Jihalvská 20, 625 00 Brno-Bohunice
Ústav hematologie a krevní transfuze, U Nemocnice 1, 128 02 Praha 2

‹‹ Back to list